Cited by 322Adrenal and Paraganglionic TumorsAdrenal Hormones and DisordersPituitary Gland Disorders and Treatments

Adrenal incidentaloma: a new cause of the metabolic syndrome?

Terzolo, Massimo, Pia, Anna, Alì, Anna, Osella, Giangiacomo, Reimondo, Giuseppe, Bovio, Silvia, Daffara, Fulvia, Procopio, Massimo +3 more·2002·The Journal of Clinical Endocrinology & Metabolism

Abstract

A number of patients with adrenal incidentaloma are exposed to a slight degree of cortisol excess resulting from functional autonomy of the adrenal mass (usually a cortical adenoma). At present, there are only scant data on the unwanted effects of this endocrine condition referred to as subclinical Cushing's syndrome. The aim of the present study was to look for some features of the metabolic syndrome in patients with incidental adrenal adenoma. Forty-one patients (9 men and 32 women) bearing adrenal incidentaloma with typical computed tomography features of cortical adenoma were studied. For both patients and controls, exclusion criteria were age equal to 70 yr or greater, previous history of fasting hyperglycemia, or impaired glucose tolerance (IGT), severe hypertension, current use of medication or concomitant relevant illnesses, and body mass index (BMI) equal to 30 kg/m(2) or greater. Forty-one patients with euthyroid multinodular goiter accurately matched for sex, age, and BMI served for a 1:1 case-control analysis. The study design included an oral glucose tolerance test (75 g) and an endocrine workup aimed at the study of the hypothalamic-pituitary-adrenal axis. Age and BMI were fully comparable between patients (54.0 +/- 10.7 yr, 23.8 +/- 2.4 kg/m(2)) and controls (52.2 +/- 11.6 yr, 23.5 +/- 2.8 kg/m(2)). Fasting glucose and fasting insulin levels were not different between the two groups (4.96 +/- 0.61 mmol/liter vs. 4.88 +/- 0.58 mmol/liter; 67 +/- 34 pmol/liter vs. 59 +/- 32 pmol/liter), but the 2-h postchallenge glucose was significantly higher in patients than in controls (7.43 +/- 2.49 mmol/liter vs. 6.10 plus minus 1.44 mmol/liter, P = 0.01). Fifteen patients (36%) reached the World Health Organization criteria for IGT and two other patients (5%) reached those for diabetes, and 14% of the controls qualified for IGT (P = 0.01). No difference in the lipid pattern was seen between the two groups, but either systolic or diastolic blood pressure were higher in patients (135.4 +/- 15.5 mm Hg vs. 125.0 +/- 15.6 mm Hg, P = 0.003; 82.9 +/- 9.1 mm Hg vs. 75.3 +/- 6.6 mm Hg, P < 0.0001). We calculated the whole-body insulin sensitivity index derived from the oral glucose tolerance test that was significantly reduced in the patients (4.3 +/- 1.7 vs. 5.7 +/- 2.5, P = 0.01). In a multiple regression analysis, 2-h glucose was associated with BMI and midnight cortisol values (r(2) = 0.36, P = 0.002). The comparison of the patients with nonfunctioning adenoma (n = 29) with those with subclinical Cushing's syndrome (n = 12) yielded significant differences as to 2-h glucose and triglyceride levels, which were significantly higher in the second group (7.02 +/- 1.76 mmol/liter vs. 8.72 +/- 3.17 mmol/liter, P = 0.03; 1.06 +/- 0.4 mmol/liter vs. 1.73 +/- 0.96 mmol/liter, P = 0.002), but the insulin sensitivity index was conversely reduced (5.2 +/- 1.4 vs. 2.9 +/- 1.2, P < 0.0001). In conclusion, many patients with incidental adrenal adenoma display altered glucose tolerance, that may be explained by reduced insulin sensitivity, and increased blood pressure levels in comparison with carefully age- and BMI-matched controls. The slight hypercortisolism observed in some such patients may significantly contribute to this state of insulin resistance. Midnight serum cortisol appears as a sensitive marker of the metabolic effects of subclinical Cushing's syndrome.

Integrity signals

Registry

Crossref · 10.1210/jcem.87.3.8277

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The 1-mg dexamethasone overnight suppression test is recommended for screening adrenal incidentaloma patients for subclinical Cushing syndrome, with a threshold of 138 nmol/L; 50 nmol/L virtually excludes subclinical Cushing syndrome, and 50-138 nmol/L is an area of uncertainty.

    “The -mg dexamethasone overnight suppression test is recommended for screening patients with AI for SCS, setting the threshold at  nmol/L; a value of  nmol/L virtually excludes SCS, whereas values between  and  nmol/L occupy an area of uncertainty ().”
  • The prevalence of impaired glucose tolerance or diabetes has been higher in patients with subclinical Cushing syndrome than in nonfunctioning adenoma or controls, but other studies did not confirm this.

    “Focusing on glucose metabolism, the prevalence of IGT or DM has been higher in patients with SCS than in cases of nonfunctioning adenoma or controls (, , , , , , ), but these data were not confirmed by other studies that found much the same prevalence of these comorbidities in SCS as in the overall series of AI and in the general population (, -).”

The citation lists haven’t been fetched yet

References 44 · Cited by 322

Authors
Terzolo, M., Pia, A., Alì, A., Osella, G., Reimondo, G., Bovio, S., Daffara, F., Procopio, M., Paccotti, P., Borretta, G., & Angeli, A.
Affiliations
  • Ospedale San Luigi Gonzaga (IT)
  • Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT)
Corresponding author
Terzolo, Massimo
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2002-03
Volume
87
Issue
3
Pages
998-1003
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2109181100
Cited by
322
References
44
Citations by year
2026: 4 · 2025: 8 · 2024: 3 · 2023: 16 · 2022: 9 · 2021: 11 · 2020: 11 · 2019: 9 · 2018: 16 · 2017: 10 · 2016: 7 · 2015: 18 · 2014: 15 · 2013: 16 · 2012: 20
FWCI
12.70
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
Keywords
adrenal incidentaloma, subclinical Cushing's syndrome, metabolic syndrome, adrenal adenoma, impaired glucose tolerance, diabetes mellitus, hypertension, hypothalamic-pituitary-adrenal axis, cortisol excess, oral glucose tolerance test, body mass index, lipid profile, insulin resistance, obesity-related hypertension, obesity-related diabetes
MeSH terms
Adenoma, Adrenal Gland Neoplasms, Adult, Aged, Blood Pressure, Cushing Syndrome, Female, Humans, Insulin, Male, Middle Aged, Reference Values, Body Mass Index, Case-Control Studies, Glucose Intolerance, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review